Deletional, mutational, and methylation analyses of CDKN2 (pI6/MTSI) in primary and merastatic prostate cancer

Genes Chromosomes and Cancer

Volumn 19, Issue 2, 1997, Pages 90-96

  Jarrard, David F ^a   Steven Bova, G ^a   Ewing, Charles M ^a   Pin, Sokhom S ^a   Nguyen, Son H ^a   Baylin, Stephen B ^a   Cairns, Paul ^a   Sidransky, David ^a   Herman, James G ^a   Isaacs, William B ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; DNA METHYLATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

AGED; AZACITIDINE; CARRIER PROTEINS; CHROMOSOME DELETION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENE EXPRESSION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR CELLS, CULTURED;

EID: 0343580444     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V     Document Type: Article

References (29)

1. Antequera F, Boyes J, Bird A (1990) High levels of de novo methylatinn and altered chromatin structure at CpG islands in cell lines. Cell 62:503-514.
2. Bartsch D, Shevlin DW, Tung WS, Kishker O, Wells SA, Goodfellow PJ (1995) Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas, Genes Chromosom Cancer 14:189-195.
3. Baylin SB, Makos M, Wu JJ, Yen RW, de Bustros A, Vertino P, Nelkin BD (1991) Abnormal patterns of DNA methylarion in human neoplasia: Potential consequences for tymor progression, [Review]. Cancer 3:383-390.
4. Berges RR, Vukamovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Walsh PC, Isaacs JI (1995) Implication of cell kinetic changes during the progression of human prostatic cancer. Clinical Cancer Res 1:473-480.
5. Bird A (1992) The essentials of DNA methylation. Cell 70:5-8.
6. Bonetta L (1994) Tumor-suppressor genes. Open questions on p16 [News; Comment]. Nature 370:180.
7. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873.
8. Brooks JD, Bova GS, Isaacs WB (1995) Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35-39.
9. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, et al (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 11:210-212.
10. Caldas C, Hahn SA, Dacosta LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:410.
11. Costello JE Berger MS, Huang S, Cavenee WK (1996) Silencing of p16 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410.
12. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA (1995) Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535.
13. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al. (1994a) Silencing of the VHL. tumor-suppressor gene by DNA methylation in carcinoma. Proc Natl Acad Sci USA 91:9700-9704.
14. Herman JG, Latif F, Weng YK, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB (1994b) Silencing of the VHL. tumor-suppressor gene by DNA methylation in renal circinoma. Proc Natl Acad Sci USA 91:9700-9704.
15. Herman JG, Merlu A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB(1995) Inactivation of Ac CDKN2/p16/ MTS1 is frequently associated with aberrant DNA methylation in all common cancers. Cancer Res 55:4525-4530.
16. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8:15-21.
17. Isaacs WB, (1995) Molecular genetics of prostate cancer. Cancer Surv 25:357-379.
18. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types [see Comments]. Science 264:436-440.
19. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J (1995) Mutational analysis of CDKN2 (CDK41/MTS1) in tissues cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625.
20. Lee W-H, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W-S, Isaacs WB, Nelson WG (1994) Cytidine methylation of regulatory sequence near the π-class glutathione-stransferase gene accompanies human prostate cancer carcinogenesis. Proc Natl Acad Sci USA 91:11735-11737.
21. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brooks J, Isaacs W, Linehan M, Baylin SB (1993) DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 53:2719-2722.
22. Merlo A, Herman JG, Mao L, Lee DJ, Gabriclson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see Comments]. Nature Med 1:686-692.
23. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB (1993) Reduction of E-cadherin levels and deletion of the α-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590.
24. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
25. INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049.
26. INK4/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451.
27. Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see Comments]. Nature 366:704-707.
28. Ueki K, Ono Y, Hensen JW, Efird JT, Vondeirnling A, Louis DN (1996) CDKN2/PL6 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153.
29. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514-517.